Abstract

Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats

Author(s): Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E

Issue: May/Jun 2017 - Volume 21, Number 3

Page(s): 242-246

Download in electronic PDF format for $75
  • Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 1
  • Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 2
  • Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 3
  • Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 4
  • Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats Page 5

Abstract

The objective of this study was to compare serum concentrations of transdermal fluoxetine compounded in Lipoderm base versus commercially available oral fluoxetine tablets. Sixteen clinically healthy, client-owned cats that were at least one year of age were enrolled. Cats weighed between three and seven kilograms, had no comorbidities, and were behavior medication naïve. Cats were recruited from January 2016 through April 2016. Eight cats were assigned to each medication group based on owner preference. The cats received either oral (1 mg/kg) or transdermal (5 mg/kg; maximum 25 mg daily) fluoxetine compounded in a transdermal base (PCCA Lipoderm), administered daily for 60 days. Serum levels of fluoxetine and norfluoxetine were assessed as a surrogate for relative efficacy. Serum was collected and analyzed by high-performance liquid chromatography-mass spectrometry/mass spectrometry at baseline and days 5, 10, 30, 45, and 60 post-drug start. Adverse effects were monitored during physical exams, speaking with owners, and laboratory analysis of liver function tests at baseline and days 5, 30, and 60 post-drug start. Serum fluoxetine concentrations significantly differed between the treatment groups at days 45 and 60 post-drug start. Norfluoxetine concentrations significantly differed at days 30, 45, and 60 post-drug start. Blood concentrations of fluoxetine and norfluoxetine significantly differed between oral and transdermal routes after 30 days of treatment. Oral fluoxetine concentrations were consistently higher. Transdermal fluoxetine appeared to be well-tolerated, but a lack of knowledge regarding effective blood levels makes it unclear if a clinical effective response would be obtained at the blood concentrations achieved.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
May/Jun 2017
Pg. 242-246
Nov/Dec 2006
Pg. 418
Author(s): Fields Shannon W
Mar/Apr 2003
Pg. 106-113
Author(s): Davidson Gigi S
Sep/Oct 2018
Pg. 409
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 327-336
Jan/Feb 2007
Pg. 73
Author(s): Allen Loyd V Jr
May/Jun 2014
Pg. 253-255
Nov/Dec 2022
Pg. 468-472
Jul/Aug 2004
Pg. 269-274
Sep/Oct 2008
Pg. 392-397
Jan/Feb 2004
Pg. 46-48
Author(s): Allen Loyd V Jr
Jan/Feb 2007
Pg. 44-48
Sep/Oct 2009
Pg. 386-389
May/Jun 2010
Pg. 182-192
May/Jun 2011
Pg. 200-203
Author(s): Wynn Tom, Goetsch Daniel
May/Jun 2004
Pg. 181-185
Mar/Apr 2020
Pg. 98-102
Author(s): Riepl Mike
Jul/Aug 2016
Pg. 271-274
Author(s): Eichstadt Lauren R
Sep/Oct 2023
Pg. 368-380
Author(s): Riepl Mike, Kaiser Joe
Nov/Dec 2017
Pg. 446-452